Banner

Comparison of Histidine rich glycoprotein, a novel biomarker for sepsis, with traditional biomarkers in adult ICU patients.

• 2022
Back
Publication Information
Authors Mohammed A. Fouad1, Ahmed H. Abd Elrahman2and Marwa S. EL-Melouk
Keywords Not Available
Journal Not Available
Publisher Not Available
Volume Not Available
Issue Not Available
Pages Not Available
publication.type Local
Paper Link Not Available
Supplementary Materials Not Available
Abstract
Sepsis is a major public healthcare problem. It remains a significant cause of morbidity and mortality
in intensive care units (ICU) all over the world. A lifesaving early specific diagnosis and treatment is a
challenge as no gold standard technique exists that can alone allow a rapid and reliable diagnosis of
sepsis. Histidine-rich glycoprotein (HRG) is a promising new biomarker of sepsis that can contribute
to enhance current sepsis diagnostic tools. The current study aimed to evaluate HRG as a diagnostic
biomarker for sepsis compared to the conventionally used biomarkers, procalcitonin (PCT) and Creactive protein (CRP). The study included 67 participants classified into 3 groups: Control (n=19),
systemic inflammatory response syndrome (SIRS) patients (n=24) and sepsis patients (n=24). Serum
HRG, CRP and PCT levels were measured by ELISA techniques. HRG level was significantly reduced in
sepsis patients compared with SIRS patients (P